USA flag logo/image

An Official Website of the United States Government

In vivo Testing of S. aureus alpha-Hemolysin Inhibitors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93402
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI082749
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INNOVATIVE BIOLOGICS, INC
INNOVATIVE BIOLOGICS, INC 13455 SUNRISE VALLEY DR, STE 200 HERNDON, VA 20171 3296
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: In vivo Testing of S. aureus alpha-Hemolysin Inhibitors
Agency: HHS
Contract: 1R43AI082749-01
Award Amount: $300,000.00
 

Abstract:

DESCRIPTION (provided by applicant): We have recently demonstrated that alpha-hemolysin produced by S. aureus plays a key role in the pathogenesis of staphylococcal pneumonia, and identified beta-cyclodextrin derivatives that potently inhibit the cytotoxic effects of this secreted bacterial toxin. The overall goal of this feasibility study is to examine the ability of these inhibitors to provide in vivo protection in a mouse model of S. aureus pneumonia. The specific aims of this Phase I study are: (1) Esta blish and validate analytical methods for the detection of cyclodextrins in biological samples. (2) Evaluate toxicity and preliminary pharmacokinetic properties of the compounds and determine the optimal dosing schedules for the efficacy studies. (3) Quant ify alpha-hemolysin inhibition by beta-cyclodextrin derivatives in a tissue culture model of human alveolar cell injury. (4) Evaluate the efficacy of beta-cyclodextrin derivatives in the prevention and treatment of S. aureus pneumonia in mice. The data der ived from this feasibility study will lay the foundation for future prophylactic and therapeutic strategies in S. aureus pneumonia, including infection caused by methicillin resistant strains. In the long-term, subsequent pre-clinical and clinical studies of these compounds will lead to the development of novel drugs against S. aureus infection. PUBLIC HEALTH RELEVANCE: Staphylococcus aureus is one of the most significant causes of serious hospital- and community-acquired bacterial infections, and a sharp i ncrease in the incidence of severe S. aureus pneumonia has been noted for nearly a decade. Increasing antimicrobial resistance among S. aureus strains and the appearance of particularly virulent isolates of this pathogen within the community have rendered conventional antimicrobial therapies obsolete, resulting in increased mortality and cost of care. Novel therapeutic approaches to both prevent and treat S. aureus-mediated invasive pulmonary infection, especially methicillin resistant S. aureus (MRSA), are necessary.

Principal Investigator:

Vladimir A. Karginov
7036225749
VAK@INNOVBIO.COM

Business Contact:

Vladimir Karginov
vak@innovbio.com
Small Business Information at Submission:

INNOVATIVE BIOLOGICS, INC
INNOVATIVE BIOLOGICS, INC 13455 SUNRISE VALLEY DR, STE 200 HERNDON, VA 20171

EIN/Tax ID: 113427236
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No